BR112015009072A2 - métodos para redução dos riscos associados à insuficiência cardíaca e fatores associados à mesma - Google Patents
métodos para redução dos riscos associados à insuficiência cardíaca e fatores associados à mesmaInfo
- Publication number
- BR112015009072A2 BR112015009072A2 BR112015009072A BR112015009072A BR112015009072A2 BR 112015009072 A2 BR112015009072 A2 BR 112015009072A2 BR 112015009072 A BR112015009072 A BR 112015009072A BR 112015009072 A BR112015009072 A BR 112015009072A BR 112015009072 A2 BR112015009072 A2 BR 112015009072A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- heart failure
- reducing
- effective amount
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
Abstract
abstract the disclosure provides methods of preventing or treating heart failure in a mammalian subject, reducing risk factors associated with heart failure, and/or reducing the likelihood or severity of heart failure. the disclosure also provides methods of preventing, or treating lv remodeling in a mammalian subject, and/or reducing the likelihood or severity of lv remodeling. the methods comprise administering to the subject an effective amount of an aromatic-cationic peptide. in some embodiments, the methods comprise administering to the subject an effective amount of an aromatic cationic peptide to reduce levels of c-reactive protein, tumor necrosis factor alpha, interleukin 6, reactive oxygen species, nt-pro bnp, and/or cardiac troponin i, and/or reduce expression levels of mlcl at1 and/or alcat 1 in subjects in need thereof. in some embodiments, the methods comprise administering to the subject an effective amount of an aromatic cationic peptide to increase expression of taz1 and/or increase mk atp activity in subjects in need thereof. _____________________________________________________________________________________________ resumo patente de invenção: "métodos para redução dos riscos associados à insuficiência cardíaca e fatores associados à mesma". a invenção fornece métodos de prevenção ou tratamento de insuficiência cardíaca em um indivíduo mamífero, redução de fatores de risco associados à insuficiência cardíaca e/ou redução da probabilidade ou gravidade de insuficiência cardíaca. a invenção também fornece métodos de prevenção ou tratamento de remodelamento de ve em um indivíduo mamífero e/ou redução da probabilidade ou gravidade de remodelamento de ve. os métodos compreendem administração, ao indivíduo, de uma quantidade eficaz de um peptídeo aromático catiônico. em algumas modalidades, os métodos compreendem administração, ao indivíduo, de uma quantidade eficaz de um peptídeo aromático catiônico para reduzir os níveis de proteína c-reativa, fator alfa de necrose tumoral, interleucina 6, espécies reativas de oxigênio, nt-pro bnp e/ou troponina i e/ou reduzir os níveis de expressão de mlcl at1 e/ou alcat 1 em indivíduos que precisam do mesmo. em algumas modalidades, os métodos compreendem administração, ao indivíduo, de uma quantidade eficaz de um peptídeo aromático catiônico para aumentar a expressão de taz1 e/ou aumentar a atividade de atp mk em indivíduos que precisam do mesmo.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261716867P | 2012-10-22 | 2012-10-22 | |
| US201361822752P | 2013-05-13 | 2013-05-13 | |
| US201361839743P | 2013-06-26 | 2013-06-26 | |
| US201361839750P | 2013-06-26 | 2013-06-26 | |
| PCT/US2013/066228 WO2014066419A2 (en) | 2012-10-22 | 2013-10-22 | Methods for reducing risks associated with heart failure and factors associated therewith |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015009072A2 true BR112015009072A2 (pt) | 2017-07-04 |
Family
ID=50545459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015009072A BR112015009072A2 (pt) | 2012-10-22 | 2013-10-22 | métodos para redução dos riscos associados à insuficiência cardíaca e fatores associados à mesma |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20150246092A1 (pt) |
| EP (4) | EP2908839B1 (pt) |
| JP (3) | JP2016503397A (pt) |
| KR (1) | KR20160009008A (pt) |
| CN (2) | CN105050613A (pt) |
| AU (2) | AU2013334788A1 (pt) |
| BR (1) | BR112015009072A2 (pt) |
| CA (1) | CA2889155A1 (pt) |
| HK (1) | HK1213799A1 (pt) |
| MX (1) | MX2015005102A (pt) |
| NI (1) | NI201500057A (pt) |
| PE (1) | PE20151434A1 (pt) |
| WO (1) | WO2014066419A2 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110339339A (zh) | 2013-03-01 | 2019-10-18 | 康德生物医疗技术公司 | 治疗线粒体疾病的方法 |
| JP6518197B2 (ja) | 2013-03-01 | 2019-05-22 | ステルス バイオセラピューティックス コープ | バース症候群の予防または治療のための方法及び組成物 |
| US10047395B2 (en) * | 2013-06-26 | 2018-08-14 | Stealth Biotherapeutics Corp | Methods and compositions for detecting and diagnosing diseases and conditions |
| CA3020393A1 (en) | 2016-04-11 | 2017-10-19 | Carnot, Llc | Chiral peptides |
| EP3474877A4 (en) * | 2016-06-24 | 2019-11-27 | University of Southern California | MENTSH ANALOGUE AS THERAPEUTICS FOR DIABETES, ADIPOSITAS AND ASSOCIATED DISEASES AND COMPLICATIONS THEREOF |
| AU2018214554C1 (en) * | 2017-02-01 | 2022-12-15 | Novo Nordisk A/S | Treatment of diuretic resistance |
| JP7395479B2 (ja) | 2018-01-05 | 2023-12-11 | ノヴォ ノルディスク アー／エス | 免疫抑制なしにｉｌ－６媒介性炎症を処置する方法 |
| KR102546547B1 (ko) | 2018-01-11 | 2023-06-22 | 삼성전자주식회사 | 보행 보조 방법 및 장치 |
| KR20220052561A (ko) | 2020-10-21 | 2022-04-28 | 장영진 | 어류 가공물 및/또는 콩 가공물을 유효성분으로 포함하는 심부전의 예방 또는 치료용 약학 조성물 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
| KR20150043568A (ko) * | 2002-07-19 | 2015-04-22 | 애브비 바이오테크놀로지 리미티드 | ＴＮＦα 관련 질환의 치료 |
| HUE027110T2 (en) * | 2003-02-04 | 2016-08-29 | Cornell Res Foundation Inc | Use of an aromatic cationic peptide |
| EP1890153A1 (en) * | 2006-08-16 | 2008-02-20 | F. Hoffman-la Roche AG | Cardiac troponin as an indicator of advanced coronary artery disease |
| EP1890154B1 (en) * | 2006-08-16 | 2012-07-04 | F. Hoffmann-La Roche AG | Cardiac troponin as an indicator of advanced coronary artery disease |
| US20080318909A1 (en) * | 2007-06-14 | 2008-12-25 | Sparagna Genevieve C | Use Of Linoleic Compounds Against Heart Failure |
| EP2262520B1 (en) * | 2008-02-26 | 2017-05-03 | Cornell University | Compositions for prevention and treatment of renal injury |
| EP3251686A1 (en) * | 2009-08-12 | 2017-12-06 | Cornell University | Methods for preventing or treating metabolic syndrome |
| JP2013506696A (ja) * | 2009-10-05 | 2013-02-28 | コーネル ユニヴァーシティー | 心不全の予防又は処置の方法 |
| MX2012005927A (es) * | 2009-11-24 | 2012-11-23 | Alder Biopharmaceuticals Inc | Anticuerpos para il-6 uso de los mismos. |
| EP2519249A4 (en) * | 2009-12-31 | 2013-06-26 | Stealth Peptides Int Inc | METHODS OF REALIZING AORTO-CORONARY BRIDGE |
| EP3090754A1 (en) * | 2009-12-31 | 2016-11-09 | Stealth Peptides International, Inc. | Methods for the prevention or treatment of vessel occlusion injury |
| US20130040901A1 (en) * | 2010-02-26 | 2013-02-14 | University Of Florida Research Foundation Inc. | Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy |
| EP2808029A3 (en) * | 2010-03-15 | 2015-04-01 | Stealth Peptides International, Inc. | Combination therapies using cyclosporine and aromatic cationic peptides |
| EP3300740A1 (en) * | 2012-08-02 | 2018-04-04 | Stealth Peptides International, Inc. | Methods for treatment of atherosclerosis |
| EP2928562A4 (en) * | 2012-12-06 | 2016-06-22 | Stealth Peptides Int Inc | PEPTIDE THERAPEUTIC PRODUCTS AND METHODS OF USE |
| US10047395B2 (en) * | 2013-06-26 | 2018-08-14 | Stealth Biotherapeutics Corp | Methods and compositions for detecting and diagnosing diseases and conditions |
| CA2916497C (en) * | 2013-06-26 | 2022-07-12 | Stealth Biotherapeutics Corp | Methods for the regulation of matrix metalloproteinase expression |
-
2013
- 2013-10-22 CN CN201380067076.XA patent/CN105050613A/zh active Pending
- 2013-10-22 CA CA2889155A patent/CA2889155A1/en not_active Abandoned
- 2013-10-22 PE PE2015000538A patent/PE20151434A1/es not_active Application Discontinuation
- 2013-10-22 JP JP2015539720A patent/JP2016503397A/ja active Pending
- 2013-10-22 WO PCT/US2013/066228 patent/WO2014066419A2/en active Application Filing
- 2013-10-22 EP EP13849406.7A patent/EP2908839B1/en active Active
- 2013-10-22 EP EP19185584.0A patent/EP3586862B1/en active Active
- 2013-10-22 BR BR112015009072A patent/BR112015009072A2/pt not_active IP Right Cessation
- 2013-10-22 CN CN201910384895.6A patent/CN110193077A/zh active Pending
- 2013-10-22 AU AU2013334788A patent/AU2013334788A1/en not_active Abandoned
- 2013-10-22 US US14/437,325 patent/US20150246092A1/en not_active Abandoned
- 2013-10-22 KR KR1020157013559A patent/KR20160009008A/ko not_active Application Discontinuation
- 2013-10-22 EP EP21197102.3A patent/EP4005582A1/en not_active Withdrawn
- 2013-10-22 EP EP24159638.6A patent/EP4397314A1/en active Pending
- 2013-10-22 MX MX2015005102A patent/MX2015005102A/es unknown
-
2015
- 2015-04-22 NI NI201500057A patent/NI201500057A/es unknown
-
2016
- 2016-02-18 HK HK16101851.8A patent/HK1213799A1/zh unknown
-
2018
- 2018-02-06 JP JP2018018942A patent/JP2018109012A/ja active Pending
- 2018-07-19 AU AU2018206766A patent/AU2018206766A1/en not_active Abandoned
-
2019
- 2019-06-04 JP JP2019104270A patent/JP2019194193A/ja active Pending
- 2019-12-20 US US16/724,076 patent/US20200360462A1/en not_active Abandoned
-
2022
- 2022-06-13 US US17/838,766 patent/US20230190859A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PE20151434A1 (es) | 2015-10-16 |
| US20150246092A1 (en) | 2015-09-03 |
| MX2015005102A (es) | 2016-02-09 |
| EP4397314A1 (en) | 2024-07-10 |
| EP2908839A2 (en) | 2015-08-26 |
| EP3586862B1 (en) | 2021-12-08 |
| AU2018206766A1 (en) | 2018-08-09 |
| CN110193077A (zh) | 2019-09-03 |
| JP2016503397A (ja) | 2016-02-04 |
| EP4005582A1 (en) | 2022-06-01 |
| EP2908839A4 (en) | 2016-06-15 |
| NI201500057A (es) | 2015-07-16 |
| AU2013334788A1 (en) | 2015-06-04 |
| US20230190859A1 (en) | 2023-06-22 |
| CN105050613A (zh) | 2015-11-11 |
| EP2908839B1 (en) | 2019-08-21 |
| JP2019194193A (ja) | 2019-11-07 |
| CA2889155A1 (en) | 2014-05-01 |
| EP3586862A1 (en) | 2020-01-01 |
| WO2014066419A3 (en) | 2014-06-12 |
| US20200360462A1 (en) | 2020-11-19 |
| WO2014066419A2 (en) | 2014-05-01 |
| KR20160009008A (ko) | 2016-01-25 |
| HK1213799A1 (zh) | 2016-07-15 |
| JP2018109012A (ja) | 2018-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015009072A2 (pt) | métodos para redução dos riscos associados à insuficiência cardíaca e fatores associados à mesma | |
| Takawale et al. | Tissue inhibitor of matrix metalloproteinase-1 promotes myocardial fibrosis by mediating CD63–integrin β1 interaction | |
| UK | Chronic heart failure in adults: diagnosis and management | |
| Penn et al. | An open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure | |
| Kuwabara et al. | MicroRNA-451 exacerbates lipotoxicity in cardiac myocytes and high-fat diet-induced cardiac hypertrophy in mice through suppression of the LKB1/AMPK pathway | |
| UY39119A (es) | Proteínas de fusión para tratar trastornos metabólicos | |
| Potter et al. | Fresh frozen plasma and spray-dried plasma mitigate pulmonary vascular permeability and inflammation in hemorrhagic shock | |
| AR083878A1 (es) | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento | |
| BR112016024379A2 (pt) | variantes ldlr e seu uso em composições para reduzir os níveis de colesterol | |
| BRPI0915780A2 (pt) | uso de uma beta defensiva de mamífero, e, método para tratar uma doença inflamatória ou distúrbio em tecidos de mamíferos | |
| ES2694667T3 (es) | Método para producir oxalato oxidasas que tienen actividad óptica cerca de pH fisiológico y uso de tales oxalato oxidasas recombinantes en el tratamiento de enfermedades relacionadas con oxalato | |
| BR112012006501A8 (pt) | Polipeptídios e usos dos mesmos | |
| BR112015004734A2 (pt) | proteínas de fusão para tratar uma síndrome metabólica | |
| BR112014018331A8 (pt) | Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação | |
| CU20140035A7 (es) | Proteínas de función dual para tratar trastornos metabólicos | |
| BR112014020233A2 (pt) | seleção de paciente com câncer para administração de inibidores sinalizantes wnt usando status de mutação rnf43 | |
| BR112014012808A2 (pt) | proteína de fusão anticâncer | |
| BR112016015660A2 (pt) | formulação farmacêutica de neuregulina (nrg) e formulação farmacêutica liofilizada de neuregulina (nrg) | |
| BR112013029062A2 (pt) | lixisenatida e metformina para o tratamento de diabetes tipo 2 | |
| BR112020008705A2 (pt) | Métodos de tratamento da insuficiência cardíaca com fração de ejeção reduzida com dapagliflozina | |
| Gao et al. | Novel role for caspase-activated DNase in the regulation of pathological cardiac hypertrophy | |
| BR112013009660A8 (pt) | Proteína de fusão com fator de atividade ix, sequência de dna e vetor recombinante | |
| CO2023000307A2 (es) | Polipéptidos de mybpc3 y usos de los mismos | |
| CO2017001899A2 (es) | Tratamiento del cáncer con el inhibidor de la alfa-amilasa en los animales de compañía | |
| BR112017005310A2 (pt) | plasmídeo recombinante otimizado por códon, técnica de indução à regeneração de nervo periférico e modalidade de tratamento de um nervo humano danificado |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2433 DE 22-08-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |